CHPA | APHC

Canadian Homeopathic Pharmaceutical Association

 
The core objective of the association is to represent the public policy and regulatory
interests of manufacturers, importers and distributors of homeopathic medicines in Canada.

MissionIntroduction to Homeopathy

Mission

Public Policy | Regulatory Interests

The core objective of the association is to represent the public policy and regulatory interests of manufacturers, importers and distributors of homeopathic medicines in Canada. In support of this objective, the CHPA/APHC conducts its activities to:
 

  • Represent the members’ interests at the federal and provincial levels in relation to legislation and regulation affecting homeopathic medicines;
  • Enhance the recognition of homeopathic medicines among consumers and health care practitioners and encourage a climate of acceptance of homeopathic medicines in Canada;
  • Promote high standards of manufacture of homeopathic medicines;
  • Advance the academic and scientific understanding of homeopathic medicines and in so doing contribute to the acceptance of homeopathic medicines in healthcare delivery in Canada.

Latest News

Position Statement on the Coronavirus 2019-nCoV

The Canadian Homeopathic Pharmaceutical Association (CHPA), representing the major manufacturers and distributors of homeopathic medicines, confirms that it is unaware of any homeopathic literature or clinical trial that specifically support the use of any...

Homeopathic Medicines in Health Care

Introduction to Homeopathy

Dr. Samuel Hahnemann developed homeopathy approximately 200 years ago. It is based on the theory of similars and the use of infinitesimal doses. The idea is that a substance that can cause certain symptoms will also cure those symptoms, when administered in an extremely diluted form.

CHPA has, since 1990, advocated the development of a comprehensive regulatory framework for HMs that would take into account the regulatory precedents for HMs established in other countries such as European Union member states and the USA. These regulatory precedents included the formal recognition of methods of manufacture of HMs (homeopathic pharmacy), indications for use, product formulations and potencies contained in internationally recognized pharmacopoeias.